You are here: Home :: Keyword index :: the bis Vie :: Trypanosoma - tumor M2-pyruvate kinase (Tu M2-PK) TTP

Items for "TTP"

Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA)

We have established a new, enzyme-linked immunosorbent assay (ELISA) for the detection of ADAMTS13 antigen using purified polyclonal rabbit anti-human ADAMTS13 IgG...

Keywords: ADAMTS13, ADAMTS13-antigen, ELISA, TTP, HUS

00/0000 | Thrombosis and Haemostasis, Schattauer

A common origin of the 4143insA ADAMTS13 mutation

Severely deficient activity of the von Willebrand Factor (VWF) cleaving metalloprotease, ADAMTS13, is associated with thrombotic thrombocytopenic purpura (TTP)...

Keywords: ADAMTS13, TTP, VWF, mutation

07/2006 | Thrombosis and Haemostasis, Schattauer

Amino acid regions 572579 and 657666 of the spacer domain of ADAMTS13 provide a common antigenic core required for binding of antibodies in patients with acquired TTP

Antibodies directed against ADAMTS13 have been detected in the majority of patients with acquired thrombotic thrombocytopenic purpura (TTP)...

Keywords: ADAMS/ADAMTS 13, autoantibodies, thrombotic thrombocytopenic purpura, TTP, HUS

09/2006 | Thrombosis and Haemostasis, Schattauer

ADAMTS-13 regulates platelet adhesion under flow. A new method for differentiation between inherited and acquired thrombotic thrombocytopenic purpura

ADAMTS-13 cleaves large and ultra-large von Willebrand factor multimers normally secreted by endothelial cells...

Keywords: ADAMTS-13, TTP, VWF, Impact-R

08/2006 | Thrombosis and Haemostasis, Schattauer

Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia

Treatment of relapsed or refractory autoimmune mediated haemolytic syndromes, such as autoimmune haemolytic anaemia (AIHA) and thrombotic thrombocytopenic purpura (TTP), represents a therapeutic challenge...

Keywords: Rituximab, TTP, AIHA